Selecting the Right Bridge-Covered GLP-1 for Older Patients With Obesity

Editor’s Note: The Medicare GLP-1 Bridge Program and the subsequent BALANCE Model are evolving federal initiatives. This information is subject to change based on upcoming CMS guidance and federal rulemaking.

Key Takeaways:

• Titrate slowly and individualize goals in older adults, watching for GI intolerance, volume depletion, and drug interactions.
• Pair every GLP-1 with a lean-mass plan – adequate protein plus resistance training – to protect against sarcopenia.
• Choose an agent the patient can sustain: Weight returns after discontinuation, so confirm a path beyond the bridge.

Glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin agents have transformed obesity medicine, yet access for older patients remains uneven. Many begin therapy through a manufacturer bridge program or an interim supply while prior authorization or plan coverage is finalized. That bridge is often time-limited, so the agent a clinician chooses at the outset frequently becomes the one the patient stays on.

For adults over 65, in whom body composition, comorbidity burden, and polypharmacy differ meaningfully from younger cohorts, the initial selection deserves deliberate attention rather than defaulting to whatever the bridge stocks.

Weighing efficacy against tolerability

The available agents differ substantially in weight-loss magnitude. In SURMOUNT-1, tirzepatide produced mean reductions of up to roughly 21% of body weight over 72 weeks in adults with obesity, and the head-to-head SURMOUNT-5 trial confirmed that tirzepatide achieves greater weight loss than semaglutide (approximately 20% versus 14%).^1,2

Greater potency, however, is not automatically the goal in geriatric care. Rapid or very large weight loss can unmask frailty, and a recent review of pharmacologic obesity treatment in older adults emphasizes individualized targets, slower titration, and vigilance for volume depletion, gastrointestinal intolerance, and interactions with existing medications.³

For a robust, comorbid older patient, the higher-efficacy agent may be appropriate. For a frailer patient, a more moderate response may be the safer bridge to sustained benefit.

Protecting lean mass and function

The most consequential geriatric concern is body composition. Substantial fat loss on incretin therapy is accompanied by loss of lean body mass, which in older adults compounds age-related sarcopenia and threatens mobility and independence.⁴

This risk is not a reason to withhold treatment – patients at high baseline sarcopenia risk can still benefit – but it does mandate mitigation, particularly adequate protein intake and structured resistance training, which can meaningfully preserve muscle during incretin-based weight loss.^5,6

Selecting a GLP-1 for an older patient, therefore, means selecting a program: The drug is one component alongside a documented plan for strength preservation. Clinicians should establish baseline functional status and monitor for decline throughout titration.⁵

Prioritizing cardiometabolic benefit

Because older patients carry a heavier cardiovascular burden, evidence of outcome benefit should weigh heavily in agent selection. In the SELECT trial – whose participants averaged 62 years – semaglutide reduced major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes, and a prespecified analysis showed consistent benefit among patients with prevalent heart failure.^7,8

Long-term follow-up further demonstrated that semaglutide's weight loss continued through ~65 weeks and was then sustained over 4 years in this older, comorbid population. Where an older patient has established atherosclerotic disease or heart failure, these data make semaglutide a well-supported bridge choice, since the coverage rationale and the clinical rationale align.⁹

Planning for the end of the bridge

A defining feature of bridge coverage is that it ends. Discontinuation matters clinically: In SURMOUNT-4, patients who stopped tirzepatide after the lead-in regained a substantial portion of lost weight, whereas those who continued, sustained and extended their weight loss.¹⁰

Counseling older patients that these are chronic therapies – not short courses – is essential before the bridge is offered. And clinicians should confirm a realistic path to continued coverage rather than initiating an agent the patient cannot maintain. When durable access is uncertain, choosing an agent with a clearer long-term coverage pathway may serve the patient better than starting the most potent option and losing it after a few weeks/months.

Individualized care

Selecting a bridge-covered GLP-1 for an older adult is a decision about efficacy, safety, and sustainability. Higher-potency agents such as tirzepatide deliver the largest weight reductions, while semaglutide offers robust, sustained cardiovascular outcome data in an older, comorbid population.^1,2,7-9

Across all agents, lean-mass preservation through protein and resistance exercise is non-negotiable in geriatric patients. Titration should be cautious, and every prescription should account for what happens when the bridge ends. Matching the agent to the individual patient – not merely to what coverage temporarily allows – is what turns a short-term bridge into a durable, function-preserving benefit.^3-6,10